Measurable disease per FET-PET vs MRI in GBM

Update: 2025-02-08

Description

Dr. Iyad Alnahhas interviews Dr. Nathalie Albert about her and her team's recent manuscript entitled: "Measurable disease as baseline criterion for response in glioblastoma: A comparison of PET-based (PET RANO 1.0) and MRI-based (RANO) assessments", published online in Neuro-Oncology in January 2025.

Comments

In Channel

QOL and cognitive functioning in patients with oligodendroglioma

2025-09-2618:22

Post-operative radiation in recurrent grade 1 meningiomas

2025-09-1219:39

mRNA CAR T against GD2 in high-grade glioma models

2025-08-2929:43

A transcriptomic atlas of CNS tumors

2025-07-1135:22

Gut microbiome in primary CNS lymphoma

2025-06-2715:04

Germline analysis of diffuse midline glioma

2025-06-0829:55

The proteomic landscape of diffuse midline glioma

2025-05-1716:55

Radio-Pathomic maps and MR perfusion

2025-04-1820:25

CSF proteomics in glioma

2025-03-2144:15

Vorasidenib in IDH mutant glioma

2025-03-0842:44

KL-50 in post TMZ MMR-deficient GBM

2025-02-2221:33

Measurable disease per FET-PET vs MRI in GBM

2025-02-0814:06

Pre-radiation chemotherapy in GBM

2025-01-2013:42

cIMPACT-NOW Update 8: grading of meningiomas

2024-12-1343:16

Residual tumor volume and survival after CCNU/TMZ in GBM

2024-11-2413:18

Alterations in RNA splicing between meningioma DNA methylation groups

2024-11-0833:46

The immune landscape of IDH mutant and IDHwt glioma

2024-10-2533:27

Equity-driven applications of AI in neuro-oncology

2024-10-0922:34

IDH mutant glioma across age groups

2024-09-2034:34

Contemporary molecular prognostic signatures in glioma

2024-08-3020:00

00:00

Measurable disease per FET-PET vs MRI in GBM

Dr. Iyad Alnahhas, Dr. Nathalie Albert

#box-pro-ellipsis-176001913850071{-webkit-line-clamp:2;}Measurable disease per FET-PET vs MRI in GBM

Measurable disease per FET-PET vs MRI in GBM

Dr. Iyad Alnahhas, Dr. Nathalie Albert

Measurable disease per FET-PET vs MRI in GBM